Fosamax vs Evenity (Romosozumab): Real-World Evidence Comparison

How Each Drug Works

Alendronate and romosozumab operate through completely different biological pathways. Alendronate inhibits osteoclast-mediated bone resorption, slowing bone loss and preserving existing bone mass. Romosozumab blocks sclerostin, a protein that normally suppresses bone formation, producing a dual effect: bone formation increases while resorption simultaneously decreases.

Alendronate: Antiresorptive Mechanism

Alendronate binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This triggers osteoclast apoptosis and reduces bone turnover markers such as serum C-telopeptide (CTX) by roughly 50 to 60% within 3 to 6 months of starting therapy. The American Association of Clinical Endocrinology 2020 guidelines recommend bisphosphonates as first-line pharmacotherapy for postmenopausal osteoporosis.

Because alendronate is antiresorptive only, it preserves the bone mineral density (BMD) you already have but produces relatively modest new bone formation. Long-term use (beyond 5 to 10 years) raises the rare risk of atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ), which is why drug holidays are recommended. The FDA label for alendronate sodium includes these risks in its prescribing information.

Romosozumab: Dual Anabolic and Antiresorptive Action

Romosozumab binds sclerostin, a Wnt-pathway inhibitor secreted by osteocytes. Blocking sclerostin releases the brake on osteoblast activity and simultaneously reduces RANKL-driven osteoclast recruitment. A 2019 phase 3 analysis published in the Journal of Bone and Mineral Research confirmed that romosozumab produced a 13.7% increase in lumbar spine BMD at 12 months, the largest BMD gain of any approved osteoporosis agent measured at that timepoint.

The dual mechanism closes the so-called "anabolic window" rapidly. Bone formation markers (P1NP) peak within the first month and return toward baseline by month 9 of the 12-month course, which is why the regimen is capped at exactly 12 monthly injections. Sclerostin inhibition and its skeletal effects are reviewed in detail in a 2017 Endocrine Reviews article.

Key Trial Data: What the Numbers Actually Show

FIT Trial (Alendronate)

The Fracture Intervention Trial (FIT) remains the foundational evidence for alendronate. In the vertebral fracture arm (N=2,027 postmenopausal women with existing vertebral fractures), alendronate 10 mg/day reduced new vertebral fractures by 47% (8.0% vs 15.0%, P<0.001) and hip fractures by 51% (1.1% vs 2.2%, P<0.05) over three years. FIT results were published in JAMA in 1998.

The hip fracture subgroup benefit in FIT was confined to women with a baseline T-score of <-2.5 at the femoral neck, a finding that shapes current prescribing guidelines. The National Osteoporosis Foundation clinical guidelines use this threshold as a key treatment initiation criterion.

FRAME Trial (Romosozumab vs Placebo)

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly for 12 months to placebo in postmenopausal women, then crossed both groups to denosumab. At 12 months, romosozumab reduced new vertebral fractures by 73% (0.5% vs 1.8%, P<0.001) and clinical fractures by 36% (1.6% vs 2.5%, P<0.01). FRAME was published in the New England Journal of Medicine in 2017.

Lumbar spine BMD increased 13.3% with romosozumab vs 0.0% with placebo at 12 months. Total hip BMD increased 6.9% vs 0.0%. These gains are roughly three times what alendronate produces over the same period. A comparative BMD analysis across osteoporosis agents was published in the Journal of Clinical Densitometry in 2020.

ARCH Trial (Romosozumab vs Alendronate, the Definitive Head-to-Head)

ARCH (N=4,093) is the only major randomized controlled trial directly comparing romosozumab to alendronate. Postmenopausal women with osteoporosis and high fracture risk received romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone throughout. After 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% versus alendronate alone (6.2% vs 11.9%, P<0.001) and nonvertebral fractures by 19% (8.7% vs 10.6%, P=0.04). Hip fractures were reduced by 38% (2.0% vs 3.2%, P=0.02). ARCH was published in the New England Journal of Medicine in 2017.

The ARCH data make a clinically important point: the benefit of romosozumab over alendronate persisted even after both groups were on alendronate, suggesting the initial anabolic phase creates a structural advantage in trabecular and cortical architecture that antiresorptive therapy alone cannot replicate.

Cardiovascular Safety: The Critical Difference

Romosozumab carries a boxed warning for myocardial infarction and stroke. In ARCH, serious cardiovascular events occurred in 2.5% of the romosozumab group vs 1.9% of the alendronate group during the first 12 months (P=0.07 for the overall trial, driven by the active treatment phase). The FDA label for romosozumab (Evenity) states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

This safety signal was not seen in FRAME (where the comparator was placebo, and a different population was enrolled), suggesting the cardiovascular risk may be partially attributable to a cardioprotective effect of alendronate in the ARCH comparator arm rather than solely to harm from romosozumab. A 2020 meta-analysis in JAMA Internal Medicine examined cardiovascular outcomes in patients on bisphosphonates and found a potential cardioprotective association, though causality is unconfirmed.

Alendronate has no boxed warnings. Its gastrointestinal profile (esophageal irritation, dysphagia) is the main tolerability concern, addressed by taking the tablet with a full glass of water while remaining upright for 30 minutes. The prescribing information for alendronate sodium details the administration requirements.

Who Should Not Receive Romosozumab

• MI or stroke within the prior 12 months
• Hypocalcemia (must be corrected before starting)
• Severe renal impairment (creatinine clearance <30 mL/min)
• Known hypersensitivity to romosozumab

Who Should Not Receive Alendronate

• Esophageal abnormalities (stricture, achalasia)
• Inability to remain upright for 30 minutes
• Creatinine clearance <35 mL/min (per FDA label)
• Hypocalcemia

Real-World Evidence Beyond Randomized Trials

Randomized trials enroll carefully selected populations. Real-world data capture adherence failures, comorbidities, and switching patterns that trials cannot.

Alendronate Adherence in Practice

A retrospective analysis of over 38,000 postmenopausal women in a U.S. Commercial claims database found that only 47% of patients initiating alendronate remained adherent (proportion of days covered ≥80%) at 12 months. This adherence data was published in Osteoporosis International in 2017. Poor adherence dramatically erodes fracture benefit. Women discontinuing bisphosphonates within 12 months lose much of the anti-fracture protection demonstrated in trials. A 2006 BMJ study showed that patients with less than 80% adherence to alendronate had a 46% higher hip fracture rate than those who were adherent.

Weekly dosing (70 mg) improved adherence versus daily dosing in comparative studies, and generic availability since 2008 has made cost less of a barrier in the U.S. The comparative adherence data between daily and weekly bisphosphonate dosing are reviewed in a 2003 Osteoporosis International meta-analysis.

Romosozumab Real-World Use Patterns

Post-approval real-world data on romosozumab are still limited by the drug's 2019 FDA approval date, but registry data are accumulating. A 2022 observational study (N=312) from a Japanese osteoporosis clinic found that 12-month romosozumab completion rates were 87%, with lumbar spine BMD gains of 10.4%, slightly lower than the 13.3% seen in FRAME, likely reflecting older patients with lower baseline BMD. This real-world Japanese cohort study was published in Archives of Osteoporosis.

A 2023 U.S. Claims analysis found that only 61% of patients who completed 12 months of romosozumab transitioned to a sequential antiresorptive agent within 6 months, despite clinical guidelines recommending immediate transition. This sequential therapy gap is described in a 2023 Osteoporosis International study. Failure to consolidate romosozumab gains with subsequent bisphosphonate or denosumab therapy allows rapid bone loss and negates much of the anabolic benefit.

Switching from Fosamax to Evenity: When and How

Switching from alendronate to romosozumab is one of the more common clinical decisions in high-fracture-risk osteoporosis management. The following framework reflects current guideline recommendations and trial sequencing data.

When Switching Is Appropriate

Switching makes clinical sense in these scenarios:

• Fracture on therapy. A patient who sustains a vertebral or hip fracture while taking alendronate has demonstrated treatment failure. Romosozumab's superior anabolic effect makes it the preferred escalation agent. The AACE/ACE 2020 clinical practice guidelines for postmenopausal osteoporosis classify romosozumab as a Tier 1 agent for very high-risk patients.
• Persistently low T-score despite adequate alendronate adherence. A femoral neck T-score remaining below <-3.0 after 3 years of alendronate therapy warrants reconsideration of the treatment approach.
• Multiple prevalent vertebral fractures at presentation. Patients with two or more existing vertebral fractures may benefit more from starting with an anabolic agent rather than an antiresorptive agent. A 2019 NEJM evidence review supports this sequencing strategy.

When Switching Is Not Appropriate

Avoid switching to romosozumab if the patient has:

• Had an MI or stroke within the past 12 months (FDA boxed warning applies)
• Uncontrolled hypertension or multiple cardiovascular risk factors without cardiology clearance
• Anticipated poor injection compliance (romosozumab requires monthly clinic visits or self-injection training)

Washout Period Considerations

No mandatory washout from alendronate is required before starting romosozumab. Alendronate's long half-life in bone (estimated 10 years) means residual antiresorptive activity persists for months to years after discontinuation. This overlap may theoretically blunt the resorption-suppression component of romosozumab's dual mechanism, though no clinical trial has demonstrated a meaningful reduction in efficacy when transitioning directly. A pharmacokinetic review of bisphosphonate bone retention covers this interaction in detail.

Post-Romosozumab Sequencing

After completing 12 months of romosozumab, sequential antiresorptive therapy is mandatory. Alendronate 70 mg weekly or denosumab 60 mg every 6 months are the two most evidence-supported options. In ARCH, patients who received romosozumab followed by alendronate had sustained BMD gains at 24 months: lumbar spine +15.2%, total hip +7.1%. These ARCH 24-month follow-up data were published in the New England Journal of Medicine.

Denosumab is often preferred for post-romosozumab sequencing in patients who cannot tolerate oral alendronate, but it requires strict adherence because stopping denosumab without transitioning to a bisphosphonate causes rapid bone loss and rebound vertebral fracture risk. The denosumab discontinuation rebound risk is described in a 2017 JBMR study.

BMD Gains: A Direct Comparison

BMD is a surrogate endpoint, not a fracture outcome, but it helps clinicians track treatment response and guides decisions about drug holidays.

| Skeletal Site | Alendronate (3 years, FIT) | Romosozumab (12 months, FRAME) | |---|---|---| | Lumbar Spine | +6.2% | +13.3% | | Total Hip | +3.9% | +6.9% | | Femoral Neck | +4.1% | +5.9% |

Romosozumab produces roughly twice the lumbar spine BMD gain in 12 months that alendronate produces in 36 months. This difference in accrual speed matters most in patients with very low baseline BMD or imminent fracture risk. Comprehensive BMD response data for both agents are available in the respective FRAME and FIT publications.

Cost, Access, and Practical Considerations

Generic alendronate costs approximately $10, $20 per month in the U.S. Without insurance. Romosozumab (Evenity) carries a wholesale acquisition cost of approximately $1,800 per monthly injection before discounts, meaning the 12-month course approaches $21,600 before insurance. CMS coverage data for romosozumab are searchable via the Medicare Drug Spending Dashboard.

Most major commercial insurers and Medicare Part D plans cover romosozumab for patients who meet high-fracture-risk criteria, often requiring documentation of a prior osteoporotic fracture or a T-score below <-2.5 with additional clinical risk factors. Amgen offers a patient assistance program (Evenity SupportPlus) for eligible uninsured or underinsured patients.

Administration is another practical difference. Alendronate is a self-administered weekly oral tablet. Romosozumab requires two subcutaneous injections of 105 mg (delivered as a pair at each monthly visit) administered by a clinician or a trained patient. Each monthly visit also warrants monitoring for injection-site reactions, which occurred in 5.1% of romosozumab patients in FRAME. Injection-site reaction rates are reported in the FRAME trial publication.

Calcium and Vitamin D: Non-Negotiable for Both Drugs

Both alendronate and romosozumab require adequate calcium and vitamin D as foundational co-therapy. Hypocalcemia is a contraindication for romosozumab and a known adverse effect of any antiresorptive or anabolic agent that increases bone mineralization. The National Institutes of Health Office of Dietary Supplements recommends 1,200 mg elemental calcium daily (diet plus supplements) and 800 to 1,000 IU vitamin D3 daily for postmenopausal women on osteoporosis therapy.

Serum 25-hydroxyvitamin D should be above 30 ng/mL before starting romosozumab. Levels below <20 ng/mL are associated with secondary hyperparathyroidism, which can accelerate bone resorption and reduce the measurable BMD response to any agent. A 2011 meta-analysis in JAMA found that combined calcium and vitamin D supplementation reduced hip fracture risk by 16% in adults over 50 years.

Side Effect Profiles Compared

| Side Effect | Alendronate | Romosozumab | |---|---|---| | Esophageal irritation / dysphagia | Common (up to 10 to 15%) | Not applicable (injectable) | | Atypical femoral fracture | Rare (<0.1% at 5 years) | Not reported (12-month course only) | | Osteonecrosis of the jaw | Very rare (<0.01% in osteoporosis doses) | Not reported | | Injection-site reactions | Not applicable | 5.1% (FRAME) | | Arthralgia / myalgia | Rare | 4.9% (FRAME) | | Serious cardiovascular events | No increased risk | 2.5% vs 1.9% alendronate (ARCH) | | Hypocalcemia | Rare | Risk increased; screen before starting |

Atypical femoral fractures with alendronate appear dose-duration dependent. The absolute risk remains below <0.1% at 5 years but rises with longer use, which is why most guidelines recommend reassessing continuation at 5 years for lower-risk patients and at 10 years for higher-risk patients. The ASBMR task force report on atypical femoral fractures provides the most comprehensive risk estimates.

Clinical Decision Summary

Choosing between alendronate and romosozumab comes down to fracture risk tier, cardiovascular status, and access.

For patients with moderate osteoporosis (T-score between <-2.5 and <-3.0, no prior fragility fracture), alendronate is the appropriate first-line choice: oral, inexpensive, with 25 years of safety data.

For patients with very high fracture risk (T-score <-3.0, one or more prior fragility fractures, or fracture on existing therapy), romosozumab's superior anabolic response justifies its cost and complexity, provided the patient has no recent cardiovascular event.

The sequence of romosozumab followed by alendronate produced the most strong fracture reduction seen in any randomized osteoporosis trial: a 48% reduction in new vertebral fractures compared to alendronate alone over 24 months in ARCH. ARCH, NEJM 2017.

Patients currently on alendronate who sustain a fracture, or who have a femoral neck T-score below <-3.0 after 3 or more years of therapy, should have a clinician-guided conversation about escalation to romosozumab within 90 days of that finding.